SunRock is a biopharmaceutical company incorporated in 2014 with the objective of developing and commercializing new oncological therapies directed against the new target CCR9 and its associates.
SunRock Biopharma develops therapeutic human antibodies directed against the Chemokine Receptor 9 (CCR9) for the treatment of acute lymphoblastic leukemia and aggressive lung, ovary, prostate, breast and melanoma carcinomas.
• Cancer therapy
• Research and development of therapeutic antibodies against cancer
• Therapeutic antibodies
Investors and collaborators
• PCT/EP2014/075578 - « Antibodies against CCR9 and applications thereof. »
• EP13382469.8 - « Antibodies against CCR9 and applications thereof. »
Juan Buela (Manager)
Edificio CiMUS. Campus Vida, Av. Barcelona,
s/n, 15782 Santiago de Compostela, La Coruña
(+34) 881 815 390